Indications › Obesity & overweight › mazdutide
mazdutide in obesity & overweight
mazdutide is not approved in the US for obesity & overweight, and has 11 trials on file here in this condition. 7 of them are phase 3 or later. The next scheduled result is 2027-05-07. Being studied in a condition is not the same as being approved for it; most such programmes end without an approval.
11 registered trials study mazdutide in obesity & overweight, 7 of them still active and 3 in phase 3. The next is due to report 2027-05-07.
- Trials on file
- 11
- Active
- 7
- Active phase 3
- 3
- Participants in active trials
- 1,191
- Sponsors
- 5
- Scheduled readouts
- 3
Scheduled to report
Dates are filed by the sponsor and move often. Each links to its own record and change history.
| Est. completion | Trial | Phase | Participants |
|---|---|---|---|
| 2027-05-07 | A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2 NCT06931028 · Innovent Biologics (Suzhou) Co. Ltd. | P3 | 260 |
| 2027-10-31 | A Study of IBI362 in Chinese Adolescents With Obesity or Overweight NCT07255209 · Innovent Biologics (Suzhou) Co. Ltd. | P3 | 180 |
| 2027-12-31 | Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity NCT07657676 · China National Center for Cardiovascular Diseases | P4 | 116 |
All trials on file
Every registered trial of mazdutide grouped under obesity & overweight, largest first. Grouping follows the registry’s own condition wording.
See the full record for mazdutide, or every molecule being studied in obesity & overweight. These are registered trials, nothing more. Most drugs tested in a new condition never get approved for it, and plenty of these will report nothing useful.